Okyo Pharma Limited (OKYO.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 09-2025 | 03-2025 | 09-2024 | 03-2024 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,220 | 1,561 | 987 | 827 | 4,045 |
| Receivables | 23 | 1,889 | 1,516 | 581 | 980 |
| TOTAL | $4,643 | $3,675 | $2,827 | $1,538 | $5,197 |
| Non-Current Assets | |||||
| PPE Net | 1 | 2 | 2 | 3 | 7 |
| TOTAL | $1 | $2 | $2 | $3 | $7 |
| Total Assets | $4,644 | $3,677 | $2,829 | $1,541 | $5,204 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 186 | N/A | 2 | N/A | 2,215 |
| Accounts payable and accrued liabilities | 7,111 | 7,900 | 8,713 | 6,128 | 2,388 |
| Accrued Expenses | 529 | 379 | 894 | 830 | 1,875 |
| TOTAL | $8,059 | $9,227 | $10,054 | $7,421 | $7,257 |
| Non-Current Liabilities | |||||
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $8,059 | $9,227 | $10,054 | $7,421 | $7,257 |
| Shareholders' Equity | |||||
| Common Shares | 151,225 | 146,717 | 144,050 | 143,113 | 131,386 |
| Retained earnings | -145,609 | -143,025 | -145,203 | -142,523 | -125,698 |
| Other shareholders' equity | -9,032 | -9,242 | -6,073 | -6,469 | -7,741 |
| TOTAL | $-3,415 | $-5,550 | $-7,226 | $-5,880 | $-2,053 |
| Total Liabilities And Equity | $4,644 | $3,677 | $2,829 | $1,541 | $5,204 |